- Book
- August 2013
- 386 Pages
- Book
- February 2013
- 512 Pages
- Book
- March 2012
- 450 Pages
- Book
- September 2010
- 484 Pages
- Book
- September 2010
- 984 Pages
- Book
- March 2010
- 784 Pages
- Book
- September 2009
- 306 Pages
- Book
- January 2024
- 496 Pages
- Book
- June 2022
- 336 Pages
- Book
- September 2019
- 448 Pages
- Book
- November 2013
- 744 Pages
- Book
- March 2012
- 472 Pages
- Book
- December 2011
- 492 Pages

The Protein Drugs market is a subset of the larger Drug Discovery industry. It focuses on the development of drugs that are based on proteins, such as monoclonal antibodies, cytokines, and growth factors. These drugs are used to treat a variety of diseases, including cancer, autoimmune disorders, and infectious diseases. Protein drugs are typically developed through recombinant DNA technology, which involves the manipulation of genetic material to create a desired protein.
The Protein Drugs market is highly competitive, with many companies vying for a share of the market. Companies in the market include AbbVie, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. These companies are engaged in research and development of new protein drugs, as well as the marketing and distribution of existing drugs. Show Less Read more